文献速递胸部肿瘤

局限期小细胞肺癌的高剂量每日一次胸部放疗:CALGB 30610(Alliance)/RTOG 0538

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
PubMed 文献 · J Clin Oncol · 2023-01-09

这项III期随机试验比较局限期小细胞肺癌患者接受45 Gy每日两次放疗与70 Gy每日一次放疗的疗效。中位随访4.7年,两组总生存无显著差异(HR 0.94,95%CI 0.76-1.17,P=0.594),中位生存分别为28.5个月和30.1个月,5年OS分别为29%和32%。研究结论认为45 Gy每日两次放疗仍是标准治疗,但该研究为胸部放疗方案选择提供了最可靠的信息。

要点

  • 70 Gy每日一次放疗相比45 Gy每日两次放疗未改善总生存(HR 0.94,95%CI 0.76-1.17,P=0.594)。
  • 中位生存:每日两次组28.5个月,每日一次组30.1个月;5年OS分别为29%和32%。
  • 两组严重不良事件(包括食管和肺部毒性)频率相似。

核心结论

  • 45 Gy每日两次放疗仍是局限期小细胞肺癌的标准治疗,但该研究为胸部放疗方案选择提供了最可靠的信息。

研究设计与样本

  • III期随机试验(CALGB 30610/RTOG 0538,NCT00632853),分两阶段进行。
  • 第一阶段将局限期患者随机分配至45 Gy每日两次、70 Gy每日一次或61.2 Gy同步推量放疗,从化疗第一或第二周期(共四周期)开始。
  • 第二阶段在计划的中期毒性分析后停止61.2 Gy组分配,研究继续以剩余两组进行。
  • 主要终点为意向治疗人群的总生存。
  • 试验于2008年3月15日开始入组,2019年12月1日关闭;本分析纳入随机分配至45 Gy每日两次(n=313)或70 Gy每日一次(n=325)的所有患者。

主要发现

  • 中位随访4.7年,每日一次组总生存未改善(死亡风险比0.94;95%CI 0.76-1.17;P=0.594)。
  • 中位生存:每日两次组28.5个月,每日一次组30.1个月。
  • 5年OS:每日两次组29%,每日一次组32%。
  • 治疗可耐受,两组严重不良事件(包括食管和肺部毒性)频率相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated. METHODS: This phase III trial, CALGB 30610/RTOG 0538 (ClinicalTrials.gov identifier: NCT00632853), was conducted in two stages. In the first stage, patients with limited-stage disease were randomly assigned to receive 45-Gy twice-daily, 70-Gy once-daily, or 61.2-Gy concomitant-boost radiotherapy, starting with either the first or second (of four total) chemotherapy cycles. In the second stage, allocation to the 61.2-Gy arm was discontinued following planned interim toxicity analysis, and the study continued with two remaining arms. The primary end point was overall survival (OS) in the intention-to-treat population. RESULTS: Trial accrual opened on March 15, 2008, and closed on December 1, 2019. All patients randomly assigned to 45-Gy twice-daily (n = 313) or 70-Gy once-daily radiotherapy (n = 325) are included in this analysis. After a median follow-up of 4.7 years, OS was not improved on the once-daily arm (hazard ratio for death, 0.94; 95% CI, 0.76 to 1.17; P = .594). Median survival is 28.5 months for twice-daily treatment, and 30.1 months for once-daily treatment, with 5-year OS of 29% and 32%, respectively. Treatment was tolerable, and the frequency of severe adverse events, including esophageal and pulmonary toxicity, was similar on both arms. CONCLUSION: Although 45-Gy twice-daily radiotherapy remains the standard of care, this study provides the most robust information available to help guide the choice of thoracic radiotherapy regimen for patients with limited-stage small-cell lung cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bogart J, Wang X, Masters G, et al. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023. PMID: 36623230. doi:10.1200/JCO.22.01359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。